Contraindicated in patients with known hypersensitivity to bexarotene or any component. If fasting triglycerides are or become elevated during therapy, institute antilipemic therapy and, if needed, reduce dose or suspend therapy. Two patients experienced cholestasis. Consider suspending or discontinuing therapy if test results reach over three times the upper limit of normal values for SGOT, SGPT, or bilirubin. Use great caution.
Urinary excretion is a minor excretory pathway for drug.
Pharmacokinetics my be altered. Use of bexarotene induce biochemical evidence of or clinical hypothyroidism in about half of all patients treated and cause a reversible reduction in thyroid hormone levels. Consider thyroid hormone supplementation in patients with laboratory evidence of hypothyroidism. Leukopenia and neutropenia rarely seen with severe sequelae or serious adverse events. Obtain WBC determination with differential at baseline and periodically during therapy.